Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.

ABSTRACT:

Background

Despite the intracranial efficacy of osimertinib, central nervous system (CNS) metastases remain a major cause of morbidity and mortality in EGFR-mutant non-small-cell lung cancer (NSCLC). The genomic drivers of CNS dissemination are poorly understood.

Patients and methods

We analyzed the clinicogenomic features of patients with EGFR-mutant NSCLC receiving first-line osimertinib with extracranial next generation sequencing (NGS) (n = 262) and individuals with intracranial NGS (n = 81). Paired extra- and intracranial NGS was available for 14 patients. Time-to-event analyses were conducted from time of metastatic diagnosis, except for time-to-treatment discontinuation (TTD), which began at treatment initiation.

Results

Among 262 patients receiving first-line

SUBMITTER: Wilcox JA 

PROVIDER: S-EPMC12507033 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature